{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:42Z","timestamp":1792114122644,"version":"4.4.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The promise of immune checkpoint inhibitors (ICIs) therapy in cancer treatment is tempered by the occurrence of immune-related adverse events (irAEs). Many patients undergoing ICIs also take aspirin, but the association between aspirin and irAEs is not well understood.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    This study analyzed adverse reaction data associated with the use of ICIs in the US Food and Drug Administration (FDA) Adverse Event Reporting System FDA Adverse Event Reporting System database, from the approval date of each drug until 1 October 2022. Multivariate logistic regression was employed to assess the association of aspirin use with irAEs in patients receiving ICIs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The results indicated that aspirin use was associated with an increased risk of irAEs in a pan-cancer analysis, with a more pronounced association in specific cancer types such as lung cancer, mesothelioma, and pancreatic cancer. However, in lymphoma, aspirin use was associated with a reduced risk of irAEs. Furthermore, aspirin use was associated with an increased risk of certain irAEs, such as anemia, colitis, myocarditis, myositis, pancreatitis, pericarditis, and pneumonia, while it was associated with a reduced risk of rash, Stevens-Johnson syndrome, and thyroiditis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study has unveiled an association between aspirin use and irAEs in cancer patients receiving ICIs therapy, emphasizing the need for individualized consideration of patients\u2019 medication history when devising cancer treatment plans to enhance efficacy and reduce risks.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1259628","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T13:28:06Z","timestamp":1700054886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database"],"prefix":"10.3389","volume":"14","author":[{"given":"Huaju","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruidan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rendong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e002588","DOI":"10.1136\/jitc-2021-002588","article-title":"T follicular helper cells: linking cancer immunotherapy and immune-related adverse events","volume":"9","author":"Baumjohann","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1158\/1078-0432.CCR-21-3452","article-title":"Facts and hopes in immunotherapy of pancreatic cancer","volume":"28","author":"Bockorny","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6TTCHER","year":"2018","journal-title":"Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e00547-21","DOI":"10.1128\/mBio.00547-21","article-title":"Aspirin modulation of the colorectal cancer-associated microbe fusobacterium nucleatum","volume":"12","author":"Brennan","year":"2021","journal-title":"mBio"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/S0140-6736(20)30799-6","article-title":"Aspirin for secondary prevention of cardiovascular disease","volume":"395","author":"Byrne","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082276","article-title":"Comedications with immune checkpoint inhibitors: involvement of the microbiota, impact on efficacy and practical implications","volume":"15","author":"Colard-Thomas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.3390\/ijms24032769","article-title":"Implication of the gut microbiome and microbial-derived metabolites in immune-related adverse events: emergence of novel biomarkers for cancer immunotherapy","volume":"24","author":"Dora","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-med-060319-120913","article-title":"Aspirin in the prevention of colorectal neoplasia","volume":"72","author":"Drew","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/molecules27238412","article-title":"Acetylsalicylic acid-primus inter pares in Pharmacology","volume":"27","author":"Fija\u0142kowski","year":"2022","journal-title":"Molecules"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/imt-2019-0064","article-title":"Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors","volume":"12","author":"Gandhi","year":"2020","journal-title":"Immunotherapy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fvets.2020.00012","article-title":"Upregulation of PD-L1 expression by prostaglandin E(2) and the enhancement of IFN-\u03b3 by anti-PD-L1 antibody combined with a COX-2 inhibitor in mycoplasma bovis infection","volume":"7","author":"Goto","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jnci\/djx277","article-title":"Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade","volume":"110","author":"Jelinic","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e003779","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1099811","DOI":"10.3389\/fonc.2023.1099811","article-title":"Cyclooxygenase-2-Prostaglandin E2 pathway: a key player in tumor-associated immune cells","volume":"13","author":"Jin","year":"2023","journal-title":"Front. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1158\/0008-5472.CAN-19-0762","article-title":"Are platelets the primary target of aspirin's remarkable anticancer activity?","volume":"79","author":"Lichtenberger","year":"2019","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell."},{"key":"B29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-pharmtox-052020-023107","article-title":"An aspirin a day: new pharmacological developments and cancer chemoprevention","volume":"63","author":"Menter","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","article-title":"Augmentation of car T-cell trafficking and antitumor efficacy by blocking protein kinase A localization","volume":"4","author":"Newick","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","article-title":"Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention","volume":"36","author":"Ornelas","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","article-title":"T-cell repertoire diversity: friend or foe for protective antitumor response?","volume":"41","author":"Porciello","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"eaai7911","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.4049\/jimmunol.1900594","article-title":"Cutting edge: targeting thrombocytes to rewire anticancer immunity in the tumor microenvironment and potentiate efficacy of PD-1 blockade","volume":"203","author":"Riesenberg","year":"2019","journal-title":"J. Immunol."},{"key":"B40","first-page":"10","volume-title":"Exploring the mechanisms underlying the cardiotoxic effects of immune checkpoint inhibitor therapies","author":"Ronen","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"100373","DOI":"10.1016\/j.iotech.2023.100373","article-title":"TCR sequencing: applications in immuno-oncology research","volume":"17","author":"Sanrom\u00e1N \u00c1","year":"2023","journal-title":"Immunooncol Technol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"836934","DOI":"10.3389\/fonc.2022.836934","article-title":"Concomitant medication effects on immune checkpoint inhibitor efficacy and toxicity","volume":"12","author":"Sieber","year":"2022","journal-title":"Front. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1940-6207.CAPR-21-0572","article-title":"The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas","volume":"15","author":"Wei","year":"2022","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"Bmj"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11912-023-01414-4","article-title":"Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities","volume":"25","author":"Yousif","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1957605","DOI":"10.1080\/2162402X.2021.1957605","article-title":"The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1053\/j.gastro.2020.05.004","article-title":"Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects","volume":"159","author":"Zhao","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1259628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T13:28:11Z","timestamp":1700054891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1259628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":54,"alternative-id":["10.3389\/fphar.2023.1259628"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1259628","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"article-number":"1259628"}}